Immunotherapy in patients with cervical cancer
https://doi.org/10.17650/1994-4098-2020-16-2-72-77
Abstract
Immunotherapy, also known as therapy with immune checkpoint inhibitors, has shown good results in the treatment of both solid tumors and hematological malignancies. Patients with diseases that were considered incurable earlier now have an opportunity for long-term disease stabilization and high frequency of clinical remissions. This review focuses on clinical benefits and toxicity profiles of immune checkpoint inhibitors used for cervical cancer, as well as on the ways to improve prognosis and indications for immunotherapy. Correct choice of biomarkers for predicting the response to immunotherapy will ensure more precise selection of patients. This review of immunotherapy methods aims to help clinicians with the indications for this relatively new treatment which has revolutionized treatment standards. Immunotherapy has many forms, including oncolytic virus therapy, chimeric antigen receptor T-cell therapy (CAR), cancer vaccines, and adoptive T-cell therapy, in particular, immune checkpoint inhibitors, first generation of which includes monoclonal antibodies against PD-1 (pembrolizumab, nivolumab, and cemiplimab), against PD-L1 (atezolizumab, avelumab, and durvalumab), and against CTLA-4 protein (ipilimumab).
About the Author
A. G. Kedrova
Federal Research and Clinical Center for Specialized Medical Care and Medical Technologies, Federal Medical and Biological Agency of the Russian Federation
Russian Federation
28 Orekhovyy Boulevard, Moscow 115682
Russian Federation
28 Orekhovyy Boulevard, Moscow 115682
References
1. Roberts K., Culleton V., Lwin Z. et al. Immune checkpoint inhibitors: Navigating a new paradigm of treatment toxicities. Asia Pac J Clin Oncol 2017;13:277–88. DOI: 10.1111/ajco.12698.
2. Einstein M.H., Schiller J.T., Viscidi R.P. et al. Clinician’s guide to human papillomavirus immunology: knowns and unknowns. Lancet Infect Dis 2009;9:347–56. DOI: 10.1016/S1473-3099(09)70108-2.
3. Arbyn M., Xu L., Simoens C. et al. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database Syst Rev 2018;5:CD009069. DOI: 10.1002/14651858.CD009069.pub3.
4. Chung H.C., Schellens J.H.M., Delord J.-P. et al. Pembrolizumab treatment of advanced cervical cancer: updated results from the phase 2 Keynote 158 study. J Clin Oncol 2018;36:5522.
5. Lheureux S., Butler M.O., Clarke B. et al. Association of ipilimumab with safety and antitumor activity in women with metastatic or recurrent human papillomavirus-related cervical carcinoma. JAMA Oncol 2018;4:e173776. DOI: 10.1001/jamaoncol.2017.3776.
6. Hollebecque A., Meyer T., Moore K.N. et al. An open-label, multicohort, phase I/II study of nivolumab in patients with virusassociated tumors (CheckMate 358): efficacy and safety in recurrent or metastatic (R/M) cervical, vaginal, and vulvar cancers. J Clin Oncol 2017;35:5504.
7. Santin A., Deng W., Frumovitz M.M. et al. A phase II evaluation of nivolumab, a fully human antibody against PD-1, in the treatment of persistent or recurrent cervical cancer. J Clin Oncol 2018;36:5536.
8. Santin A., Deng W., Frumovitz M.M. et al. A phase II evaluation of nivolumab, a fully human antibody against PD-1, in the treatment of persistent or recurrent cervical cancer. J Clin Oncol 2018;36:5536.
9. FDA label for Pembrolizumab. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125514s014lbl.pdf.
10. Stevanović S., Pasetto A., Helman S.R. et al. Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer. Science 2017;356:200–5. DOI: 10.1126/science.aak9510.
11. Chung H.G., Ros W., Delord J.P. et al. Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study. Clin Oncol 2019;37(17):1470–8. DOI: 10.1200/JCO.18.01265.
12. Frenel J.S., du Rusquec P., de Calbiac O. et al. Clinical utility of pembrolizumab in the management of advanced solid tumors: An evidence-based review on the emerging new data. Cancer Manag Res 2019;11:4297–312. DOI: 10.2147/CMAR.S151023.
13. Lheureux S., Butler M.O., Clarke B. et al. Association of ipilimumab with safety and antitumor activity in women with metastatic or recurrent human papillomavirus-related cervical carcinoma. JAMA Oncol 2018;4(7):e173776. DOI: 10.1001/jamaoncol.2017.3776.
14. Hollebecque A., Meyer T., Moore K. et al. An open-label, multicohort, phase I/II study of nivolumab in patients with virusassociated tumors (CheckMate 358): Efficacy and safety in recurrent or metastatic (R/M) cervical, vaginal, and vulvar cancers. Clin Oncol 2017;35 (15 Suppl):5504–14. DOI: 10.1200/JCO.2017.35.15_suppl.5504.
15. Santin A., Deng W., Frumovitz M. et al. A phase II evaluation of nivolumab, a fully human antibody against PD-1, in the treatment of persistent or recurrent cervical cancer. Clin Oncol 2018;36 (15 Suppl):5536–40. DOI: 10.1200/JCO.2018.36.15_suppl.5536.
16. Tewari K.S., Vergote I., Oaknin A. et al. GOG3016/ENGOT-cx9: An open-label multi-national, randomized, phase 3 trial of cemiplimab, an anti-PD-1, versus investigator’s choice chemotherapy in 2 line recurrent or metastatic cervical cancer. Ann Oncol 2018;29 (Suppl 9):ix79–86. DOI: 10.1093/annonc/mdy436.
17. Shapira-Frommer R., Alexandre J., Monk B. et al. KEYNOTE-826: A phase 3, randomized, double-blind, placebocontrolled study of pembrolizumab plus chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer. Clin Oncol 2018;36 (15 Suppl):5536–40. DOI: 10.1200/JCO.2018.36.15_suppl.5536.
18. Efficacy and safety of BCD-100 (antiPD-1) in combination with platinumbased chemotherapy with and without bevacizumab as first-line treatment of subjects with advanced cervical cancer (FERMATA). Available at: https://clinicaltrials.gov/ct2/show/NCT03912415.
19. Rubin K.M., Kottschade L.A. Supportive care and management of treatmentrelated adverse effects from immune checkpoint inhibitors and targeted therapies in melanoma. J Adv Pract Oncol 2018;9:57–71.
20. Huh W.K., Dizon D.S., Powell M.A. et al. ADXS11-001 immunotherapy in squamous or non-squamous persistent/ recurrent metastatic cervical cancer. Results from stage I of the phase II GOG/ NRG0265 study. J Clin Oncol 2016;34:5516.
21. Postow M.A., Sidlow R., Hellmann M.D. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 2018;378:158–68.
22. Kim H.D., Park S.H. Immunological and clinical implications of immune checkpoint blockade in human cancer. Arch Pharm Res 2019;42(7):567–81. DOI: 10.1007/s12272-019-01140-1.
23. Guo C.S., Sandhu A. Managing toxicities of immune checkpoint inhibitors. Cancer Forum 2018;42:64–91.
24. Tang H., Liang Y., Anders R.A. et al. PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression. J Clin Invest 2018;128:580–8.
Review
For citations:
Kedrova A.G. Immunotherapy in patients with cervical cancer. Tumors of female reproductive system. 2020;16(2):72-77. (In Russ.) https://doi.org/10.17650/1994-4098-2020-16-2-72-77
Views:
2042
Email this article 